Pfizer deal aims for greater drug specificity
This article was originally published in Scrip
Pfizer is trying to make some of its drugs assets more tissue-specific. It has entered a preclinical collaboration with Cambridge, Massachusetts-based BIND Therapeutics to develop and commercialize highly selective, targeted and programmable drugs.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.